Table II.
Serum CA125, HE4 and ROMA levels according to histology, FIGO stage and tumor grade.
| Premenopausal | Postmenopausal | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CA125 (U/ml) | HE4 (pmol/l) | ROMA (%) | CA125 (U/ml) | HE4 (pmol/l) | ROMA (%) | |||||||
| Median | Range | Median | Range | Median | Range | Median | Range | Median | Range | Median | Range | |
| Ovarian cancer (all) | 265.4 | 14.0–4,638.8 | 89.5 | 15.0–1,500.0 | 32.3 | 3.2–99.7 | 416.9 | 9.0–5,887.0 | 470.3 | 15.0–4,940.0 | 95.2 | 4.5–100.0 |
| Serous | 352.4 | 14.0–4,638.8 | 99.7 | 15.0–1,500.0 | 35.2 | 2.0–99.7 | 425.0 | 9.0–5,887.0 | 555.9 | 18.0–4,940.0 | 96.3 | 4.5–100.0 |
| Mucinous | 27.0 | 26.4–37.9 | 51.9 | 45.4–75.6 | 8.4 | 6.2–18.0 | 87.2 | 11.3–600.0 | 76.4 | 15.0–538.0 | 52.9 | 7.8–95.8 |
| Clear cell | 146.3 | 95.8–196.8 | 75.8 | 49.4–102.1 | 21.1 | 8.1–34.1 | 787.5 | 96.4–1,725.5 | 276.9 | 76.0–849.9 | 94.2 | 44.2–98.2 |
| Endometrioid | 500.0 | 500.0 | 64.5 | 64.5 | 21.0 | 21.0 | 448.8 | 41.5–2,996.9 | 390.0 | 46.1–1,235.0 | 94.8 | 26.7–99.3 |
| FIGO stage | ||||||||||||
| I and II | 95.8 | 14.0–1,252.0 | 64.5 | 15.0–211.6 | 18.0 | 2.5–75.1 | 174.9 | 9.0–2,347.0 | 108.8 | 15.0–1,235.0 | 56.8 | 4.5–99.3 |
| III and IV | 543.5 | 64.3–4,638.8 | 343.3 | 20.7–1,500.0 | 90.7 | 9.0–99.7 | 540.0 | 18.0–5,887.0 | 639.0 | 62.8–4,940.0 | 96.9 | 25.0–100.0 |
| Grade | ||||||||||||
| 1 | 69.7 | 25.3–459.7 | 47.7 | 15.0–414.3 | 7.2 | 2.5–93.9 | 66.5 | 9.0–245.0 | 86.4 | 18.0–283.5 | 47.1 | 4.5–85.9 |
| 2 | 389.1 | 14.0–2,096.0 | 94.1 | 20.7–1,500.0 | 44.5 | 8.4–99.7 | 415.9 | 41.5–5,659.0 | 385.3 | 35.0–3,608.0 | 94.6 | 26.7–99.0 |
| 3 | 350.8 | 54.3–4,638.8 | 211.6 | 20.4–1,500.0 | 75.1 | 2.0–99.7 | 559.1 | 11.2–5,109.8 | 639.0 | 30.0–4,001.0 | 97.0 | 12.0–100 |
| Borderline tumors | 38.9 | 5.4–206.3 | 51.0 | 39.2–89.0 | 8.0 | 4.0–25.3 | 79.9 | 6.7–421.2 | 103.8 | 40.1–274.2 | 49.0 | 5.0–88.0 |
| Other cancers and metastatic ovarian tumors | 42.4 | 8.2–1,090.7 | 50.4 | 32.9–356.6 | 7.4 | 2.6–91.0 | 93.7 | 11.1–4,855.4 | 81.6 | 15.0–580.1 | 43.1 | 8.0–94.9 |
| Benign diseases (all) | 22.7 | 2.4–2,257.0 | 44.2 | 15.0–269.8 | 5.8 | 2.0–99.3 | 15.6 | 2.3–1,255.0 | 56.4 | 15.0–282.6 | 12.9 | 1.1–88.8 |
| Endometriosis | 46.8 | 8.8–377.0 | 45.2 | 17.8–86.7 | 6.4 | 1.8–24.1 | 18.9 | 6.7–82.1 | 47.2 | 27.5–73.0 | 11.4 | 1.8–35.3 |
| Teratoma tumors | 15.9 | 7.7–51.9 | 44.4 | 26.3–69.1 | 5.8 | 1.7–14.7 | 15.3 | 6.3–18.2 | 49.1 | 45.7–72.4 | 11.2 | 6.7–17.9 |
| Cystadenoma tumors | 22.3 | 8.6–125.9 | 41.4 | 15.0–101.6 | 5.2 | 2.2–32.8 | 19.2 | 2.3–272.0 | 56.9 | 15.0–282.6 | 14.9 | 1.1–86.4 |
| Follicular cysts | 4.6 | 9.1–88.0 | 43.5 | 24.2–84.7 | 5.5 | 1.6–22.1 | 11.7 | 3.2–79.8 | 65.7 | 41.5–206.5 | 13.1 | 5.3–65.7 |
| Paraovarian cysts | 15.3 | 4.1–111.4 | 48.2 | 36.4–78.0 | 7.1 | 3.7–18.5 | 9.3 | 4.9–502.7 | 52.0 | 40.5–186.8 | 8.7 | 4.8–87.0 |
| Hemorrhagic cysts | 14.6 | 5.5–274.8 | 44.2 | 24.8–88.6 | 5.7 | 1.7–23.3 | – | – | – | – | – | – |
| Inflammatory tumors | 101.4 | 2.4–1,670.6 | 54.3 | 39.0–269.8 | 9.3 | 3.8–83.1 | – | – | – | – | – | – |
| Cirrhosis | 2,257.0 | 2,257.0 | 109.2 | 109.2 | 41.3 | 41.3 | 254.9 | 161.3–1,256.0 | 167.8 | 115.8–199.2 | 83.4 | 75.7–88.8 |
| BRCA1 mutations | 15.5 | 3.0–148.1 | 34.2 | 15.0–109.1 | 3.2 | 2.4–33.6 | 15.2 | 3.0–36.3 | 51.3 | 15.0–83.9 | 10.6 | 3.9–26.8 |
-, no diagnoses made; CA125, carbohydrate antigen 125; HE4, human epididymis protein 4; ROMA, Risk of Ovarian Malignancy Algorithm; FIGO, International Federation of Gynecology and Obstetrics; BRCA1, breast cancer 1.